⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
XNCR News
Xencor, Inc.
Form 8-K
sec.gov
XNCR
Bispecific Antibody Market Landscape Report 2026: A Potential $60 Opportunity by 2031 - Insight on More than 550 Clinical Trials - Antibody Dosage, Patent, Price, Sales & Outlook
globenewswire.com
JNJ
AMGN
GMAB
ABBV
AZN
PFE
BMY
REGN
XNCR
ZYME
Ledger Run First to Bring AI-Powered Automation to Clinical Trial Payments
prnewswire.com
XNCR
Antheia Appoints Dr. Chris Savile as Vice President of Business Development and Partnerships
prnewswire.com
XNCR
CDXS
Xenocor Appoints David McNally as Chief Executive Officer, Antony Watson to Chief Commercial Officer and David Van Ness to Chief Technology Officer
prnewswire.com
XNCR
CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight
prnewswire.com
GILD
INCY
BIIB
NVS
AMGN
JNJ
ABBV
BMY
AZN
MRK
PFE
TGTX
XNCR
CABA
IMUX
ZNTL
GLPG
CLNN
AUTL
Form 8-K
sec.gov
XNCR
Form 8-K
sec.gov
XNCR
Xencor Announces Change to Ultomiris® Royalty Revenue Forecast
businesswire.com
XNCR
Form 8-K
sec.gov
XNCR